Provided by Tiger Trade Technology Pte. Ltd.

Sunshine Biopharma Inc.

0.6876
-0.0854-11.05%
Post-market: 0.70000.0124+1.80%18:42 EDT
Volume:132.58K
Turnover:94.31K
Market Cap:2.67M
PE:-0.07
High:0.7800
Open:0.7800
Low:0.6715
Close:0.7730
52wk High:24.30
52wk Low:0.6715
Shares:3.88M
Float Shares:3.81M
Volume Ratio:1.49
T/O Rate:3.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.0329
EPS(LYR):-14.3739
ROE:-21.92%
ROA:-9.91%
PB:0.10
PE(LYR):-0.05

Loading ...

Sunshine Biopharma Shareholder Consent Authorizes Reverse Stock Split of up to 1-for-20

Reuters
·
Sep 28

Sunshine Biopharma launches generic Zofran in Canada

TIPRANKS
·
Sep 24

Sunshine Biopharma Files Draft Information Statement on Potential Reverse Stock Split up to 1-for-20

Reuters
·
Sep 17

Sunshine Biopharma - Board Authorized to Effect Reverse Split of Common Stock up to 1-for-20 - SEC Filing

THOMSON REUTERS
·
Sep 17

Sunshine Biopharma Inc: Advances Lead Coronavirus Drug Candidate into Ind-Enabling Studies

THOMSON REUTERS
·
Sep 16

Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies

Reuters
·
Sep 16

Sunshine Biopharma Cuts Warrant Exercise Price to 1.2

Reuters
·
Sep 12

Health Canada: Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions

THOMSON REUTERS
·
Aug 31

Health Canada Approves Sunshine Biopharma Atenolol Tablets for Canada Market

Reuters
·
Aug 31

Sunshine Biopharma Director Andrew Keller Declines to Seek Board Reelection

Reuters
·
Aug 29

Sunshine Biopharma provides update, outlines plans for oncology project

TIPRANKS
·
Aug 26

Sunshine Biopharma Wins Canadian Approval for Generic Enalapril Tablets

Reuters
·
Aug 19

Sunshine Biopharma: Enalapril Expected to Begin Shipping to Canadian Pharmacies by Year-End 2026

THOMSON REUTERS
·
Aug 19

Sunshine Biopharma: Receives Canadian Regulatory Approval for Enalapril

THOMSON REUTERS
·
Aug 19

Sunshine Biopharma Q2 Net Loss Narrows 11.67% to $1.56 Million; Revenue Slips 1.6% to $9.26 Million

Reuters
·
Aug 14

Sunshine announces approval of generic Dienogest tablets for Canadian market

TIPRANKS
·
Aug 04

Sunshine Biopharma Cuts Exercise Price of Outstanding Series B Warrants to $1.22

Reuters
·
Aug 03

Sunshine Biopharma Receives Health Canada Approval for Generic Ondansetron to Treat Chemotherapy-Induced Nausea

MT Newswires Live
·
Jul 28

Sunshine Biopharma announces approval of generic Ondansetron tablets

TIPRANKS
·
Jul 28

Sunshine Biopharma - Enters At-the-market Sales Agreement with Aegis Capital for up to $4 Mln - SEC Filing

THOMSON REUTERS
·
Jul 21